Meeting News Coverage

Addition of daclatasvir to interferon-based HCV therapy improved treatment response, shortened duration

October 9, 2013
SAN FRANCISCO – Patients with hepatitis C treated with daclatasvir in addition to pegylated interferon and ribavirin had better response rates…
Meeting News Coverage

Interferon-free regimen safe, effective for patients with HCV genotype 1

October 8, 2013
A regimen of daclatasvir, asunaprevir, and a non-nucleoside NS5B inhibitor yielded high sustained virologic response rates among patients with…
Meeting News Coverage

Several factors predicted interferon-based therapy response in HIV/HCV coinfection

October 7, 2013
SAN FRANCISCO — Factors including pretreatment hepatitis C RNA and ALT levels, CD4, age and race may predict acute HCV treatment response among…
Meeting News Coverage

HCV transmitted from organ donor with negative nucleic acid test

October 5, 2013
SAN FRANCISCO — Two recipients of organs from a single donor developed hepatitis C infection that was traced back to the donor, who was…
In the Journals

Fibrosis progression common in HIV/HCV coinfection; linked to serum transaminase

October 2, 2013
Elevated serum transaminase levels are potential noninvasive markers of fibrosis, which is common and can progress rapidly among patients coinfected…

FDA maintains clinical hold for sovaprevir

October 1, 2013
The FDA will not remove a clinical hold placed on sovaprevir, an NS3 protease inhibitor in development for the treatment of chronic hepatitis C…
In the Journals

Telaprevir-based triple therapy outweighed risks for adverse events

September 30, 2013
Researchers reported that the treatment benefits associated with telaprevir-based triple therapy for HCV offset any problems with adverse events, and…
In the Journals

Danoprevir improved SVR rate from peginterferon/ribavirin therapy in HCV patients

September 27, 2013
Patients with hepatitis C genotype 1 treated with danoprevir in addition to pegylated interferon and ribavirin experienced high rates of sustained…
In the Journals

Resource utilization for HCV unchanged, Medicare patient responsibility increased over time

September 24, 2013
While total resource utilization for Medicare beneficiaries with hepatitis C did not change during a 6-year period, the amount of patient…
In the Journals

Severe anemia risk remains in TVR-based triple therapy for HCV

September 20, 2013
Patients with HCV who were treated with telaprevir in combination with pegylated interferon alfa-2b and ribavirin therapy remained at a significantly…